Show simple item record

dc.contributor.author Goras, Dina
dc.date.accessioned 2020-07-04T15:30:16Z
dc.date.available 2020-07-04T15:30:16Z
dc.date.issued 2018
dc.identifier.citation GORAS, Dina. Genetic aspects in Parkinson's disease. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 212. en_US
dc.identifier.uri https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/10916
dc.description Department of Molecular Biology and Human Genetics, Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova en_US
dc.description.abstract Introduction. Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement. Although the etiology of Parkinson disease is still unclear, most cases are hypothesized to be due to a combination of genetic- 10% and environmental factors. Aim of the study. Evaluation of the genetic and environmental factors in etiopathogenesis of Parkinson's disease. Study of the molecular mechanisms involved in the etiology of PD; Evaluation of the major genes for higher risk of PD; Estimating the role of environmental and genetic factors in the onset, development and prognosis PD; Prospects survey prevention and treatment of PD. Materials and methods. Scientific articles review. Results. A total of 18 loci in various genes have now been proposed for PD. Mutations within 6 of these loci (SNCA, LRRK2, PRKN, DJ1, PINK1, and ATP 13A2) are well-validated causes of familial parkinsonism. Inheritance is autosomal dominant for SNCA and LRRK2. Inheritance is autosomal recessive for PRKN, DJ1, PINK1, and ATP13A2. Stem cell therapy for Parkinson’s disease (Embryonic Stem Cells/ induced Pluripotent Stem Cells (iPSCs) that are adult cells (e.g. skin cells)) is a potential treatment for PD, because the most significant neuronal degeneration is site and type specific (ie, dopaminergic); the target area is well defined (ie, striatum); postsynaptic receptors are relatively intact. Gene therapy has distinct theoretical advantages over conventional treatment for Parkinson's disease as it might preserve or restore dopaminergic neurons through the use of growth factors or alternatively increase the availability of enzymes required for dopamine synthesis. Conclusions. Neurodegeneration in PD is due to three interrelated molecular mechanisms: changes oxiative, mitochondrial dysfunction and degradation of proteins affected. Major genes are involved in Parkinson disease: SNCA, LRRK2, PRKN, DJ1, PINK1, ATP13A2, GBA. Environmental and genetic factors play an important role in the onset, development and prognosis BP, and they can vary from one patient to another and will depend on the root cause. Perspentivele in prevention and treatment of PD are presimptomatic screening and gene therapy. en_US
dc.language.iso en en_US
dc.publisher MedEspera en_US
dc.subject Parkinson's disease(PD) en_US
dc.subject genetic factors en_US
dc.subject environment factors en_US
dc.subject stem cell therapy en_US
dc.subject gene therapy en_US
dc.title Genetic aspects in Parkinson's disease en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2018
    The 7th International Medical Congress for Students and Young Doctors, May 3-5, 2018

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics